Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 10/20 | 0.57 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2650712 | 0.81 | SMN1; SMN2 (0.54) | FFAR2MEN1MAPTKMT2ACCNE1 | |
| SCHEMBL5652094 | 0.81 | RAB9A (0.54) | MEN1MAPTKMT2ANPC1LMNA | |
| SCHEMBL12469108 | 0.79 | FFAR2 (0.50) | FFAR2CCR2MEN1KMT2AAHR | |
| Ammonia Solution, Strong SCHEMBL27867504 | 0.79 | SMN1; SMN2 (0.52) | FFAR2MEN1MAPTKMT2ACCNE1 | |
| SCHEMBL2371104 | 0.78 | FFAR2 (0.52) | FFAR2MAPTCCNE1CDK2LMNA | |
| SCHEMBL10864137 | 0.77 | FFAR2 (0.40) | FFAR2MEN1MAPTKMT2ACCNE1 | |
| SCHEMBL5653949 | 0.77 | CCNE1 (0.55) | FFAR2MEN1MAPTKMT2ACCNE1 | |
| SCHEMBL4394535 | 0.77 | FFAR2 (0.49) | FFAR2 | |
| SCHEMBL28562030 | 0.74 | FFAR2 (0.47) | FFAR2CCNE1CDK2CDK5NPC1 | |
| SCHEMBL640631 | 0.73 | FFAR2 (0.52) | FFAR2CCR2CCNE1CDK2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168962-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-20090221824-A1 | ENANTIOSELECTIVE PROCESS | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-7582632-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| US-20080242869-A1 | Tri(Cyclo) Substituted Amide Compounds | PROSIDION LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| EP-1594867-B1 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | PROSIDION LTD (GB) | 2008-04-09 | — | — | EP | disclosed |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-7262196-B2 | Tri(cyclo) substituted amide glucokinase activator compounds | PROSIDION LIMITED (GB) | 2007-08-28 | — | — | US | disclosed |
| US-7214681-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| EP-1778678-A1 | ENANTIOSELECTIVE PROCESS | Prosidion Limited (GB) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006016178-A1 | ENANTIOSELECTIVE PROCESS | PROSIDION LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| EP-1594863-A1 | TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS | Prosidion Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
| EP-1594867-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
| US-20040186290-A1 | Tri(cyclo) substituted amide glucokinase activator compounds | OSI PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | OSI PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004072066-A1 | TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS | PROSIDION LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004072031-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | PROSIDION LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242869-A1 | Tri(Cyclo) Substituted Amide Compounds | IAPP, GPR119, CPT1A | FFAR2 905/4885CCR2 2207/4885MEN1 2209/4885 |
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | GPR119, IAPP, SLC5A1 | FFAR2 876/4885CCR2 2365/4885MEN1 2147/4885 |
| US-20090221824-A1 | ENANTIOSELECTIVE PROCESS | ADH1A, ALAD, ADH5 | FFAR2 1858/4885CCR2 3499/4885MEN1 3011/4885 |
| US-20040186290-A1 | Tri(cyclo) substituted amide glucokinase activator compounds | GCKR, GCK, GALK1 | FFAR2 1377/4885CCR2 3184/4885MEN1 4067/4885 |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | IAPP, GPR119, SLC5A1 | FFAR2 986/4885CCR2 2528/4885MEN1 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.